Company Interview / Race to better cancer treatment

Daniel Tillett from Race Oncology (ASX:RAC) highlights the phase one trial initiation of RC220, aimed at solid tumour patients. This trial explores the safe dosage of RC220, a reimagined formulation of an older drug, known for its heart-damaging side effects, aiming to protect the heart while treating cancer effectively.

RC220, combined with doxorubicin, targets a variety of cancers including lung, breast, and ovarian cancer. It addresses the challenges of chemotherapy-related heart damage, offering renewed hope for patients with exhausted treatment options. The trial spans ten sites across Australia, Hong Kong, and South Korea, ensuring diverse population efficacy.

Funded by supportive shareholders, Race Oncology (ASX:RAC) boasts $18M in cash to propel these trials. Daniel emphasises the potential societal impact, transforming investments into tangible cancer treatments rather than mere financial ventures. He invites more shareholder involvement to further this life-saving journey.